CY1109662T1 - Ενωσεις πυρρολοτριαζινης ως αναστολεις κινασης - Google Patents

Ενωσεις πυρρολοτριαζινης ως αναστολεις κινασης

Info

Publication number
CY1109662T1
CY1109662T1 CY20091101326T CY091101326T CY1109662T1 CY 1109662 T1 CY1109662 T1 CY 1109662T1 CY 20091101326 T CY20091101326 T CY 20091101326T CY 091101326 T CY091101326 T CY 091101326T CY 1109662 T1 CY1109662 T1 CY 1109662T1
Authority
CY
Cyprus
Prior art keywords
compounds
formula
suspensions
motion
growth factor
Prior art date
Application number
CY20091101326T
Other languages
English (en)
Inventor
Brian E Fink
Ashvinikumar V Gavai
Gregory D Vite
Ping Chen
Harold Mastalerz
Derek J Norris
John S Tokarski
Yufen Zhao
Wen-Ching Han
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of CY1109662T1 publication Critical patent/CY1109662T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Η παρούσα εφεύρεση παρέχει ενώσεις του τύπου (I)• και φαρμακευτικώς αποδεκτά άλατα αυτών. Οι ενώσεις του τύπου (I) αναστέλλουν την ενεργότητα τύπου τυροσινοκινάσης σε υποδοχείς αυξητικών παραγόντων όπως HER1, HER2 και HER4, καθιστώμενες έτσι χρήσιμες ως αντιπολλαπλασιαστικούς παράγοντες. Οι ενώσεις του τύπου (I) είναι επίσης χρήσιμες για την αγωγή άλλων παθήσεων συνδεόμενων με πορείες μεταγωγής σήματος οι οποίες λειτουργούν μέσω υποδοχέων αυξητικών παραγόντων.
CY20091101326T 2003-12-29 2009-12-21 Ενωσεις πυρρολοτριαζινης ως αναστολεις κινασης CY1109662T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53333503P 2003-12-29 2003-12-29
EP04815269A EP1699797B1 (en) 2003-12-29 2004-12-23 Pyrrolotriazine compounds as kinase inhibitors

Publications (1)

Publication Number Publication Date
CY1109662T1 true CY1109662T1 (el) 2014-08-13

Family

ID=34748887

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20091101326T CY1109662T1 (el) 2003-12-29 2009-12-21 Ενωσεις πυρρολοτριαζινης ως αναστολεις κινασης

Country Status (32)

Country Link
US (4) US7141571B2 (el)
EP (2) EP2058314A1 (el)
JP (1) JP4740878B2 (el)
KR (1) KR100839716B1 (el)
CN (1) CN1922182B (el)
AR (1) AR047076A1 (el)
AT (1) ATE443706T1 (el)
AU (1) AU2004312413C1 (el)
BR (1) BRPI0418231A (el)
CA (1) CA2552107C (el)
CL (1) CL2009001492A1 (el)
CY (1) CY1109662T1 (el)
DE (1) DE602004023324D1 (el)
DK (1) DK1699797T3 (el)
ES (1) ES2331842T3 (el)
GE (1) GEP20105081B (el)
HK (1) HK1088332A1 (el)
HR (1) HRP20090601T1 (el)
IL (1) IL176450A0 (el)
MX (1) MXPA06007038A (el)
MY (1) MY145634A (el)
NO (1) NO20062763L (el)
NZ (2) NZ548070A (el)
PE (1) PE20050679A1 (el)
PL (1) PL1699797T3 (el)
PT (1) PT1699797E (el)
RU (1) RU2373209C2 (el)
SI (1) SI1699797T1 (el)
TW (1) TWI332840B (el)
UA (1) UA89038C2 (el)
WO (1) WO2005066176A1 (el)
ZA (1) ZA200605160B (el)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6867300B2 (en) * 2000-11-17 2005-03-15 Bristol-Myers Squibb Company Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors
RU2375363C2 (ru) * 2002-04-23 2009-12-10 Бристол-Маерс Сквибб Компани Пирролотриазиновые производные анилина, полезные в качестве ингибиторов киназы
US20060014741A1 (en) * 2003-12-12 2006-01-19 Dimarco John D Synthetic process, and crystalline forms of a pyrrolotriazine compound
MY145634A (en) * 2003-12-29 2012-03-15 Bristol Myers Squibb Co Pyrrolotriazine compounds as kinase inhibitors
US7102002B2 (en) * 2004-06-16 2006-09-05 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
US7173031B2 (en) * 2004-06-28 2007-02-06 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
TW200600513A (en) * 2004-06-30 2006-01-01 Bristol Myers Squibb Co A method for preparing pyrrolotriazine compounds
US7253167B2 (en) * 2004-06-30 2007-08-07 Bristol-Myers Squibb Company Tricyclic-heteroaryl compounds useful as kinase inhibitors
US7504521B2 (en) * 2004-08-05 2009-03-17 Bristol-Myers Squibb Co. Methods for the preparation of pyrrolotriazine compounds
TW200618803A (en) 2004-08-12 2006-06-16 Bristol Myers Squibb Co Process for preparing pyrrolotriazine aniline compounds useful as kinase inhibitors
TW200635927A (en) * 2004-12-22 2006-10-16 Bristol Myers Squibb Co Synthetic process
DE602006004976D1 (de) 2005-03-28 2009-03-12 Bristol Myers Squibb Co Kompetitive atp-kinasehemmer
US20060235020A1 (en) * 2005-04-18 2006-10-19 Soojin Kim Process for preparing salts of 4-[[5-[(cyclopropylamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-propylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide and novel stable forms produced therein
MY150958A (en) 2005-06-16 2014-03-31 Astrazeneca Ab Compounds for the treatment of multi-drug resistant bacterial infections
ES2432361T3 (es) * 2005-12-02 2013-12-03 Bayer Healthcare, Llc Derivados de pirrolotriazina útiles para el tratamiento de cáncer por inhibición de cinasa Aurora
US8063208B2 (en) * 2006-02-16 2011-11-22 Bristol-Myers Squibb Company Crystalline forms of (3R,4R)-4-amino-1-[[4-[(3-methoxyphenyl)amino]pyrrolo[2,1-f][1,2,4]triazin-5-yl]methyl]piperidin-3-ol
US20100136137A1 (en) * 2006-11-01 2010-06-03 Bristol-Meyers Squibb Company Therapeutic combination of a panher/vegfr2 kinase inhibitor and a platinum compound
WO2008103248A1 (en) 2007-02-08 2008-08-28 Codexis, Inc. Ketoreductases and uses thereof
US20090076034A1 (en) * 2007-09-14 2009-03-19 Protia, Llc Deuterium-enriched bms-690514
PT2231662E (pt) * 2007-12-19 2011-09-12 Genentech Inc 8-anilinoimidazopiridinas e o seu uso como agentes anticancerígenos e/ou anti-inflamatórios
JP2010209058A (ja) * 2008-09-29 2010-09-24 Sumitomo Chemical Co Ltd １−置換−トランス−４−（置換アミノ）ピペリジン−３−オールの製造方法
US8445676B2 (en) * 2008-10-08 2013-05-21 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
WO2010071885A1 (en) 2008-12-19 2010-06-24 Cephalon, Inc. Pyrrolotriazines as alk and jak2 inhibitors
CA2750047A1 (en) 2009-01-21 2010-07-29 Basilea Pharmaceutica Ag Novel bicyclic antibiotics
CN102482281A (zh) * 2009-07-28 2012-05-30 宇部兴产株式会社 吡咯并[2，3-d]嘧啶衍生物
ES2550667T3 (es) 2010-02-18 2015-11-11 Vtv Therapeutics Llc Derivados de fenilheteroarilo y métodos de uso de los mismos
MX2012015023A (es) 2010-06-30 2013-04-03 Fujifilm Corp Derivado novedoso de nicotinamida o sal del mismo.
CN102153558B (zh) * 2011-02-23 2012-11-21 扬州永济医药新技术有限公司 多靶点抗肿瘤抑制剂2-氨吡咯-三嗪的衍生物及其合成方法
DE102011119127A1 (de) * 2011-11-22 2013-05-23 Merck Patent Gmbh 3-Cyanaryl-1H-pyrrolo[2.3-b]pyridin-Derivate
CN103450204B (zh) 2012-05-31 2016-08-17 中国科学院上海药物研究所 吡咯[2，1-f][1，2，4]并三嗪类化合物，其制备方法及用途
US9724352B2 (en) 2012-05-31 2017-08-08 Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences Pyrrolo[2,1-F[1,2,4]triazine compounds, preparation methods and applications thereof
TW201414737A (zh) 2012-07-13 2014-04-16 必治妥美雅史谷比公司 作爲激酶抑制劑之咪唑并三□甲腈
WO2015054358A1 (en) 2013-10-11 2015-04-16 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
EP3805233B1 (en) * 2014-01-13 2024-03-06 Aurigene Oncology Limited (r) and (s) enantiomers of n-(5-(3-hydroxypyrrolidin-1-yl)-2-morpholinooxazolo[4,5-b]pyridin-6-yl)-2-(2-methylpyridin-4-yl)oxazole-carboxamide as irak4 inhibitors for the treatment of cancer
WO2015175561A1 (en) * 2014-05-12 2015-11-19 Quest Diagnostics Investments Incorporated Quantitation of tamoxifen and metabolites thereof by mass spectrometry
AR112027A1 (es) 2017-06-15 2019-09-11 Biocryst Pharm Inc Inhibidores de alk 2 quinasa que contienen imidazol
WO2019214651A1 (zh) * 2018-05-08 2019-11-14 南京明德新药研发有限公司 作为选择性HER2抑制剂的吡咯并[2,1-f][1,2,4]三嗪类衍生物及其应用
WO2021088987A1 (zh) * 2019-11-08 2021-05-14 南京明德新药研发有限公司 作为选择性her2抑制剂的盐型、晶型及其应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2163399A1 (en) 1994-11-24 1996-05-25 Katsuhiro Kawano Triazine derivative, chymase activity inhibitor and nitric oxide production inhibitor
EA002769B1 (ru) 1996-08-28 2002-08-29 Пфайзер Инк. Замещенные 6,5-гетеробициклические производные
EP1183033B1 (en) 1999-05-21 2006-03-01 Bristol-Myers Squibb Company Pyrrolotriazine inhibitors of kinases
US6982265B1 (en) 1999-05-21 2006-01-03 Bristol Myers Squibb Company Pyrrolotriazine inhibitors of kinases
JP4623483B2 (ja) * 1999-08-23 2011-02-02 塩野義製薬株式会社 ｓＰＬＡ２阻害作用を有するピロロトリアジン誘導体
AU2002232760B2 (en) 2000-11-17 2006-12-14 Bristol-Myers Squibb Company Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors
US6670357B2 (en) * 2000-11-17 2003-12-30 Bristol-Myers Squibb Company Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors
US6867300B2 (en) * 2000-11-17 2005-03-15 Bristol-Myers Squibb Company Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors
TW200300350A (en) * 2001-11-14 2003-06-01 Bristol Myers Squibb Co C-5 modified indazolylpyrrolotriazines
DE60325469D1 (de) * 2002-04-23 2009-02-05 Bristol Myers Squibb Co Als kinase inhibitoren geeignete arylketonpyrrolotriazin-verbindungen
RU2375363C2 (ru) 2002-04-23 2009-12-10 Бристол-Маерс Сквибб Компани Пирролотриазиновые производные анилина, полезные в качестве ингибиторов киназы
US6894066B2 (en) 2002-05-09 2005-05-17 Bernard Charles Sherman Magnesium salt of S-omeprazole
TW200407143A (en) 2002-05-21 2004-05-16 Bristol Myers Squibb Co Pyrrolotriazinone compounds and their use to treat diseases
US6933386B2 (en) 2002-07-19 2005-08-23 Bristol Myers Squibb Company Process for preparing certain pyrrolotriazine compounds
TWI329112B (en) 2002-07-19 2010-08-21 Bristol Myers Squibb Co Novel inhibitors of kinases
AU2003265349A1 (en) 2002-08-02 2004-02-23 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
TW200420565A (en) * 2002-12-13 2004-10-16 Bristol Myers Squibb Co C-6 modified indazolylpyrrolotriazines
US7102001B2 (en) * 2003-12-12 2006-09-05 Bristol-Myers Squibb Company Process for preparing pyrrolotriazine
MY145634A (en) 2003-12-29 2012-03-15 Bristol Myers Squibb Co Pyrrolotriazine compounds as kinase inhibitors
US7064203B2 (en) * 2003-12-29 2006-06-20 Bristol Myers Squibb Company Di-substituted pyrrolotriazine compounds
US7102002B2 (en) * 2004-06-16 2006-09-05 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
US7102003B2 (en) * 2004-07-01 2006-09-05 Bristol-Myers Squibb Company Pyrrolotriazine compounds
US7151176B2 (en) 2004-10-21 2006-12-19 Bristol-Myers Squibb Company Pyrrolotriazine compounds

Also Published As

Publication number Publication date
CN1922182A (zh) 2007-02-28
WO2005066176A1 (en) 2005-07-21
SI1699797T1 (sl) 2010-04-30
IL176450A0 (en) 2006-10-05
US20060264438A1 (en) 2006-11-23
RU2373209C2 (ru) 2009-11-20
NZ548070A (en) 2009-02-28
US20050182058A1 (en) 2005-08-18
AR047076A1 (es) 2006-01-04
EP1699797B1 (en) 2009-09-23
JP4740878B2 (ja) 2011-08-03
CN1922182B (zh) 2010-08-18
ATE443706T1 (de) 2009-10-15
PT1699797E (pt) 2009-12-29
CA2552107A1 (en) 2005-07-21
UA89038C2 (en) 2009-12-25
US7141571B2 (en) 2006-11-28
MXPA06007038A (es) 2006-08-31
NZ573544A (en) 2010-04-30
MY145634A (en) 2012-03-15
HRP20090601T1 (hr) 2009-12-31
PE20050679A1 (es) 2005-09-25
US20090048244A1 (en) 2009-02-19
GEP20105081B (en) 2010-09-27
US20110039838A1 (en) 2011-02-17
NO20062763L (no) 2006-09-11
EP2058314A1 (en) 2009-05-13
US7297695B2 (en) 2007-11-20
TW200526226A (en) 2005-08-16
DK1699797T3 (da) 2010-01-04
CL2009001492A1 (es) 2010-01-15
AU2004312413C1 (en) 2011-01-27
TWI332840B (en) 2010-11-11
KR20060107828A (ko) 2006-10-16
CA2552107C (en) 2011-10-18
BRPI0418231A (pt) 2007-04-27
US7846931B2 (en) 2010-12-07
AU2004312413A1 (en) 2005-07-21
EP1699797A1 (en) 2006-09-13
ES2331842T3 (es) 2010-01-18
JP2007518721A (ja) 2007-07-12
DE602004023324D1 (de) 2009-11-05
KR100839716B1 (ko) 2008-06-19
ZA200605160B (en) 2007-12-27
RU2006127396A (ru) 2008-02-10
PL1699797T3 (pl) 2010-02-26
HK1088332A1 (en) 2006-11-03
AU2004312413B2 (en) 2010-07-22

Similar Documents

Publication Publication Date Title
CY1109662T1 (el) Ενωσεις πυρρολοτριαζινης ως αναστολεις κινασης
ATE482212T1 (de) Pyrrolotriazinverbindungen
CY1112628T1 (el) Νεοι αναστολεις κινασης
TW200420565A (en) C-6 modified indazolylpyrrolotriazines
HUS2100028I1 (hu) ERBB I. típusú receptor tirozinkináz-gátló N4-fenil-kinazolin-4-amin származékok és rokon vegyületeik a hiperproliferatív betegségek kezelésére
MXPA04004492A (es) Indazolilpirrolotriazinas c-5 modificadas.
ATE349434T1 (de) Lactamderivaten zur verwendung als humane 11cby rezeptorantagonisten
CY1106801T1 (el) Νεες ετεροκυκλικες ενωσεις, η παρασκευη τους και η χρηση τους ως φαρμακα, ιδιαιτερα ως αντιβακτηριακα
EA200301213A1 (ru) Лиганды рецепторов 5-ht и их применение
CY1105253T1 (el) Ετepοπολυκυκλικες ενωσεις και η χρησιμοποιηση τους ως ανταγωνιστες μεταβολοτροπου γλουταμινικου υποδοχεως
CY1109543T1 (el) Βασικοι μη-πεπτιδικοι ανταγωνιστες βραδυκινινης και 5 φαρμακευτικες συνθεσεις απο αυτους
PT1379520E (pt) Antagonistas (nao-aril)-heterociclicos n-substituidos de nmda/nr2b
CY1109998T1 (el) Ενδυναμωτες υποδοχεων γλουταμινικου
CY1111656T1 (el) Παραγωγα αλφα-αμινοαμιδιου χρησιμα εις την θεραπευτικη αγωγη εθιστικων παθησεων
DE602005023124D1 (de) Spirobenzodioxole und deren verwendung als cb1-antagonisten
ATE399770T1 (de) Tachykininrezeptorantagonisten
WO2005065266A3 (en) Di-substituted pyrrolotriazine compounds
EA200301143A1 (ru) Производные гетероциклилалкокси-, алкилтио- и -алкиламинобензазола в качестве лигандов 5-гидрокситриптамина-6
CY1112135T1 (el) Ανταγωνιστες υποδοχεα il-8
DE60221813D1 (de) Thiazolopyrimidinderivate und deren verwendung als antagonisten des cx3cr1 rezeptors
PL372769A1 (en) Cyanoguanidine prodrugs
ATE407133T1 (de) 2-imidazo-benzothiazole als adenosin-rezeptor liganden
ATE298742T1 (de) Zykloalkenylsulfonamidderivate
DE602006004976D1 (de) Kompetitive atp-kinasehemmer
CY1107980T1 (el) Παραγωγα τετραϋδροκινολινης και η χρηση τους ως ρυθμιστες του υποδοχεα της fsh (ωοθυλακιοτροπου ορμονης)